Neoadjuvant DOS treatment for advanced esophageal cancer

A phase II study of treatment with neoadjuvant docetaxel, oxaliplatin plus S-1 for advanced esophageal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041210023

Enrollment

Registered

2021-05-21

Start date

2021-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer Esophageal cancer

Interventions

Neoadjuvant docetaxel, oxaliplatin plus S-1 treatment and surgery

Neoadjuvant chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Clinical stage II/III/IVa thoracic esophageal cancer 2) Histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma or basaloid-squamous cell carcinoma 3) Clinical T1-3 4) Ages between 20 years and 79 years 5) Performance status (PS) 0-1 6) Adequate function of vital organs, including bone marrow, liver, and kidney 7) Written informed consent

Exclusion criteria

Exclusion criteria: 1) History (within 3 years) of malignancies 2) Active infectious disease 3) Psychiatric disease 4) Continuous systemic steroid therapy 5) Allergy of docetaxel, oxaliplatin or S-1 6) Persistent intestinal bleeding 7) Ineligible for the study at the physician's assessment

Design outcomes

Primary

Measure	Time frame
Pathological response rate	—

Secondary

Measure	Time frame
Overall survival time, disease-free survival time, R0 resection rate, response rate (RECIST v1.0), treatment completion rate, complication rate	—

Contacts

Public ContactMitsuro Kanda

Nagoya University Graduate School of Medicine

m-kanda@med.nagoya-u.ac.jp+81-52-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026